# Blue Ridge Bankshares, Inc.: financial statements, quarterly

BRBS · NYSE · CIK 842717 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/brbs.md) · [Financials](/companies/brbs/financials.md) · [Filings](/companies/brbs/filings.md) · [Insiders](/companies/brbs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/brbs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [20.3](/filings/0000950170-23-063784.md) | [21.4 d](/filings/0000950170-24-032267.md) | [22.2](/filings/0000950170-24-055532.md) | [20.5](/filings/0000950170-24-091820.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(4.7)](/filings/0000950170-24-122469.md) | [(1.7) d](/filings/0000950170-25-036301.md) | [(0.4)](/filings/0000950170-25-065867.md) | [(0.6)](/filings/0000950170-25-104110.md) | [0.6](/filings/0001193125-25-264940.md) | [(0.7) d](/filings/0001193125-26-104410.md) | [(0.5)](/filings/0001193125-26-206547.md) | [0.5](/filings/0001193125-26-342578.md) | [1.9](/filings/0001193125-25-264940.md) | [1.1 d](/filings/0001193125-26-104410.md) | [0.3](/filings/0001193125-26-206547.md) | [(0.3)](/filings/0001193125-26-342578.md) |
| Net income | $m | [(41.4)](/filings/0000950170-24-122469.md) | [(5.8) d](/filings/0000950170-25-036301.md) | [(2.9)](/filings/0000950170-25-065867.md) | [(11.4)](/filings/0000950170-25-104110.md) | [0.9](/filings/0001193125-25-264940.md) | [(2.0) d](/filings/0001193125-26-104410.md) | [(0.4)](/filings/0001193125-26-206547.md) | [1.3](/filings/0001193125-26-342578.md) | [5.6](/filings/0001193125-25-264940.md) | [4.2 d](/filings/0001193125-26-104410.md) | [0.8](/filings/0001193125-26-206547.md) | [(1.3)](/filings/0001193125-26-342578.md) |
| Diluted EPS | $ per share | [(2.18)](/filings/0000950170-24-122469.md) | not reported | [(0.15)](/filings/0000950170-25-065867.md) | [(0.47)](/filings/0000950170-25-104110.md) | [0.01](/filings/0001193125-25-264940.md) | not reported | [(0.01)](/filings/0001193125-26-206547.md) | [0.01](/filings/0001193125-26-342578.md) | [0.06](/filings/0001193125-25-264940.md) | not reported | [0.01](/filings/0001193125-26-206547.md) | [(0.01)](/filings/0001193125-26-342578.md) |
| Basic EPS | $ per share | [(2.18)](/filings/0000950170-24-122469.md) | not reported | [(0.15)](/filings/0000950170-25-065867.md) | [(0.47)](/filings/0000950170-25-104110.md) | [0.01](/filings/0001193125-25-264940.md) | not reported | [(0.01)](/filings/0001193125-26-206547.md) | [0.01](/filings/0001193125-26-342578.md) | [0.06](/filings/0001193125-25-264940.md) | not reported | [0.01](/filings/0001193125-26-206547.md) | [(0.01)](/filings/0001193125-26-342578.md) |

- Revenue: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total assets | $m | [3,263](/filings/0000950170-24-122469.md) | [3,118](/filings/0000950170-25-036301.md) | [3,076](/filings/0000950170-25-065867.md) | [2,933](/filings/0000950170-25-104110.md) | [2,945](/filings/0001193125-25-264940.md) | [2,737](/filings/0001193125-26-104410.md) | [2,685](/filings/0000950170-25-065867.md) | [2,555](/filings/0000950170-25-104110.md) | [2,497](/filings/0001193125-25-264940.md) | [2,433](/filings/0001193125-26-342578.md) | [2,414](/filings/0001193125-26-206547.md) | [2,327](/filings/0001193125-26-342578.md) |
| Total liabilities | $m | [3,080](/filings/0000950170-23-063784.md) | [2,932](/filings/0000950170-25-036301.md) | [2,895](/filings/0000950170-24-055532.md) | [2,607](/filings/0000950170-24-091820.md) | [2,608](/filings/0000950170-24-122469.md) | [2,409](/filings/0001193125-26-104410.md) | [2,347](/filings/0000950170-25-065867.md) | [2,211](/filings/0000950170-25-104110.md) | [2,141](/filings/0001193125-25-264940.md) | [2,109](/filings/0001193125-26-342578.md) | [2,137](/filings/0001193125-26-206547.md) | [2,052](/filings/0001193125-26-342578.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [183](/filings/0000950170-24-122469.md) | [186](/filings/0001193125-26-104410.md) | [181](/filings/0000950170-25-104110.md) | [326](/filings/0001193125-25-264940.md) | [336](/filings/0001193125-25-264940.md) | [328](/filings/0001193125-26-342578.md) | [338](/filings/0001193125-26-342578.md) | [344](/filings/0001193125-26-342578.md) | [356](/filings/0001193125-25-264940.md) | [324](/filings/0001193125-26-342578.md) | [277](/filings/0001193125-26-342578.md) | [275](/filings/0001193125-26-342578.md) |

- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.9 d](/filings/0000950170-24-122469.md) | [20.5 d](/filings/0000950170-25-036301.md) | [(7.5)](/filings/0000950170-25-065867.md) | [(4.8) d](/filings/0000950170-25-104110.md) | [24.1 d](/filings/0001193125-25-264940.md) | [(18.1) d](/filings/0001193125-26-104410.md) | [(3.6)](/filings/0001193125-26-206547.md) | [10.7 d](/filings/0001193125-26-342578.md) | [6.4 d](/filings/0001193125-25-264940.md) | [0.1 d](/filings/0001193125-26-104410.md) | [15.0](/filings/0001193125-26-206547.md) | [1.7 d](/filings/0001193125-26-342578.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-122469.md) | [0.2 d](/filings/0000950170-25-036301.md) | [0.1](/filings/0000950170-25-065867.md) | [0.2 d](/filings/0000950170-25-104110.md) | [0.2 d](/filings/0001193125-25-264940.md) | [0.1 d](/filings/0001193125-26-104410.md) | [0.0](/filings/0001193125-26-206547.md) | [0.1 d](/filings/0001193125-26-342578.md) | [0.7 d](/filings/0001193125-25-264940.md) | [0.8 d](/filings/0001193125-26-104410.md) | [0.5](/filings/0001193125-26-206547.md) | [0.2 d](/filings/0001193125-26-342578.md) |
| Dividends paid | $m | [0.0 d](/filings/0000950170-24-122469.md) | [0.0 d](/filings/0000950170-25-036301.md) | [0.0](/filings/0000950170-24-055532.md) | [0.0 d](/filings/0000950170-24-091820.md) | [0.0 d](/filings/0000950170-24-122469.md) | [0.0 d](/filings/0001193125-26-104410.md) | [0.0](/filings/0001193125-26-206547.md) | [0.0 d](/filings/0001193125-26-342578.md) | not reported | not reported | [0.1](/filings/0001193125-26-206547.md) | [53.0 d](/filings/0001193125-26-342578.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [18.9](/filings/0000950170-23-063784.md) | [18.9](/filings/0000950170-24-055532.md) | [18.9](/filings/0000950170-24-091820.md) | [19.0](/filings/0000950170-24-122469.md) | [19.2](/filings/0000950170-25-065867.md) | [24.5](/filings/0000950170-25-104110.md) | [87.1](/filings/0001193125-25-264940.md) | [86.0](/filings/0001193125-26-206547.md) | [95.9](/filings/0001193125-26-342578.md) | [99.4](/filings/0001193125-25-264940.md) | [99.8](/filings/0001193125-26-206547.md) | [88.5](/filings/0001193125-26-342578.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 89,688,853 at 2026-07-31, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342578.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.